Tenax Therapeutics develops pharmaceutical products containing imatinib for pulmonary arterial hypertension treatment in the US. Products include TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) with completed phase II clinical trials. They also develop TNX-201 (imatinib) for chronic myeloid leukemia treatment. The company was previously known as Oxygen Biotherapeutics and changed its name to Tenax Therapeutics in 2014. Founded in 1967, the company is based in North Carolina.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 1.6 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.9 |